# Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study

Study · id `cardio:ct-nct01121835` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01121835](<https://clinicaltrials.gov/study/NCT01121835>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01121835

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 934 participants.

## Technical summary

Registry record NCT01121835. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2012-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 934 participants (enrolled count; ClinicalTrials.gov record NCT01121835, source copy `cardio:ctgov-nct01121835-2013-04-04`, retrieved 2026-10-26)
- Start date: 2010-02 (registry gives no type) (ClinicalTrials.gov record NCT01121835, source copy `cardio:ctgov-nct01121835-2013-04-04`, retrieved 2026-10-26)
- Primary completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01121835, source copy `cardio:ctgov-nct01121835-2013-04-04`, retrieved 2026-10-26)
- Completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01121835, source copy `cardio:ctgov-nct01121835-2013-04-04`, retrieved 2026-10-26)
- Countries: Austria; Brazil; China; Colombia; Denmark; Greece; India; Italy; Kuwait; Mexico; Romania; South Korea; Spain; Taiwan; Türkiye; United Arab Emirates (ClinicalTrials.gov record NCT01121835, source copy `cardio:ctgov-nct01121835-2013-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01121835-2013-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
- Acronym: GALAPAGOS
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): INSULIN GLARGINE
- Intervention (Drug): INSULIN GLULISINE
- Intervention (Drug): PREMIXED INSULIN
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 9078d6097398ae2cf435fd9fce6e4472f47fbc17e2ffdc247d45a4480f224220
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
